Simultaneous delivery of Wharton’s jelly mesenchymal stem cells and insulin-like growth factor-1 in acute myocardial infarction

Document Type : Research article

Authors

1 Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences,Tehran,Iran.

2 Department of Hematology, Tarbiat Modares University, Tehran, Iran.

3 Iran polymer and petrochemical institute, Tehran, Iran.

4 Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Biomedical Engineering Division, Chemical Engineering Department, Tarbiat Modares University, Tehran, Iran.

6 Faculty of veterinary medicine, University of Tehran, Tehran, Iran.

Abstract

Wharton’s jelly mesenchymal stem cells (HWJMSCs) hold promise for myocardial regeneration, but optimal treatment regimen (preferably with a growth factor) is required to maximize functional benefits. The aim of this study was to explore the cardioprotective and angiogenesis effects of HWJMSCs combined with insulin-like growth factor-1 (IGF-1) in the treatment of acute myocardial infarction.
The hydrogel consisted of Polyethylene glycol (PEG) and hyaluronic acid was prepared and characterized with regards to rheology, morphology, swelling, degradation, and release behaviors. To examine in vivo effects, the hydrogels containing HWJMSCs either alone (Cells/hydrogel group) or with IGF-1 (Cells/hydrogel/IGF-1 group) were intra-myocardially injected into a rabbit myocardial infarction model. In vivo efficacy was evaluated histological, immunohistochemical, echocardiography, scanning electron microscopy, and SPECT analyses. Eight weeks after infusion, the Cells/hydrogel and Cells/hydrogel/IGF-1 groups exhibited significantly increased left ventricular ejection fraction by echocardiography. Percent of ejection fraction were respectively 18.5% and 40% greater than control (P<0.01). Vascular density (CD31 positive cells) of both treatment groups were more than the control group and this superiority was more remarkable in Cells/hydrogel/IGF-1 group. Cells/hydrogel/IGF-1 group showed the least defect size in SPECT analysis. Combinatory therapy with HWJMSCs and IGF-1 may additionally improve cardiac function and promote angiogenesis.

Keywords

Main Subjects


Wakai AP. Myocardial infarction (ST-elevation). BMJ
Clin. Evid
. (2009) 2009: 0202
Skinner JS and Cooper A. Secondary prevention of

ischaemic cardiac events.
BMJ Clin. Evid . (2011)
2011: 0206

Hynes B, Kumar AH, OꞌSullivan J, Klein Buneker

C, Leblond AL, Weiss S, Schmeckpeper J, Martin

K and Caplice N M. Potent endothelial progenitor

cell-conditioned media-related anti-apoptotic,

cardiotrophic, and pro-angiogenic effects post-

myocardial infarction are mediated by insulin-like

growth factor-1.
Eur. Heart J. (2013) 34: 782-9.
Rizk NN, Myatt-Jones J, Rafols J and Dunbar JC.

Insulin like growth factor-1 (IGF-1) decreases

ischemia-reperfusion induced apoptosis and necrosis

in diabetic rats.
Endocrine (2007) 31: 66-71.
Fontana L, Vinciguerra M and Longo VD. Growth

factors, nutrient signaling, and cardiovascular aging.

Circ. Res
. (2012) 110: 1139-50.
Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura

J, Baserga R and Anversa P. Overexpression of insulin-

like growth factor-1 in mice protects from myocyte

death after infarction, attenuating ventricular dilation,

wall stress, and cardiac hypertrophy.
J. Clin. Invest.
(1997) 100: 1991-9.

OꞌSullivan JF, Leblond AL, Kelly G, Kumar AH,

Metharom P, Buneker CK, Alizadeh-Vikali N, Hristova

I, Hynes BG, OꞌConnor R and Caplice NM. Potent

long-term cardioprotective effects of single low-dose

insulin-like growth factor-1 treatment postmyocardial

infarction.
Circ. Cardiovasc. Interv. (2011) 4: 327-35.
Haleagrahara N, Chakravarthi S and Mathews

L. Insulin like growth factor-1 (IGF-1) causes
overproduction of IL-8, an angiogenic cytokine and

stimulates neovascularization in isoproterenol-induced

myocardial infarction in rats.
Int. J. Mol. Sci . (2011)
12: 8562-74.

Cochain C, Channon KM and Silvestre JS.

Angiogenesis in the infarcted myocardium.
Antioxid.
Redox. Signal
. (2013) 18: 1100-13.
Sun YY, Du ZH and Zhao YX. Disruption of Circadian

Rhythms and Sleep in Critical Illness: Potential

Implications for Angiogenesis After Myocardial

Infarction. A Review.
Curr. Pharm. Des . (2015) 21:
3523-32.

Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M,

Liao R, Colucci WS and Walsh K. Disruption of

coordinated cardiac hypertrophy and angiogenesis

contributes to the transition to heart failure.
J. Clin.
Invest
. (2005) 115: 2108-18.
Mitsos S, Katsanos K, Koletsis E, Kagadis GC,

Anastasiou N, Diamantopoulos A, Karnabatidis D and

Dougenis D. Therapeutic angiogenesis for myocardial

ischemia revisited: basic biological concepts and focus

on latest clinical trials.
Angiogenesis (2012) 15: 1-22.
Henning RJ. Therapeutic angiogenesis: angiogenic

growth factors for ischemic heart disease.
Future
Cardiol
. (2016) 12.
Krawiec JT and Vorp DA. Adult stem cell-based tissue

engineered blood vessels: a review.
Biomaterials
(2012) 33: 3388-400.

Vimalraj S and Selvamurugan N. MicroRNAs

expression and their regulatory networks during

mesenchymal stem cells differentiation toward

osteoblasts.
Int. J. Biol. Macromol . (2014) 66: 194-
202.

Prockop DJ. Repair of tissues by adult stem/progenitor

cells (MSCs): controversies, myths, and changing

paradigms.
Mol. Ther. (2009) 17: 939-46.
Anversa P, Rota M, Urbanek K, Hosoda T, Sonnenblick

EH, Leri A, Kajstura J and Bolli R. Myocardial aging-

-a stem cell problem.
Basic Res. Cardiol. (2005) 100:
482-93.

Nekanti U, Mohanty L, Venugopal P, Balasubramanian

S, Totey S and Ta M. Optimization and scale-up of

Whartonꞌs jelly-derived mesenchymal stem cells for

clinical applications.
Stem. Cell Res. (2010) 5: 244-54.
Lupu M, Khalil M, Andrei E, Iordache F, Pfannkuche

K, Neef K, Georgescu A, Buzila C, Brockmeier K,

Maniu H and Hescheler J. Integration properties of

Whartonꞌs jelly-derived novel mesenchymal stem cells

into ventricular slices of murine hearts.
Cell. Physiol.
Biochem
. (2011) 28: 63-76.
Kim DW, Staples M, Shinozuka K, Pantcheva P,

Kang SD and Borlongan CV. Whartonꞌs jelly-derived

mesenchymal stem cells: phenotypic characterization

and optimizing their therapeutic potential for clinical

applications.
Int. J. Mol. Sci. (2013) 14: 11692-712.
Zhang W, Liu XC, Yang L, Zhu DL, Zhang YD, Chen Y

and Zhang HY. Whartonꞌs jelly-derived mesenchymal

stem cells promote myocardial regeneration and

cardiac repair after miniswine acute myocardial

infarction.
Coron. Artery. Dis. (2013) 24: 549-58.
Gao LR, Chen Y, Zhang NK, Yang XL, Liu HL, Wang

ZG, Yan XY, Wang Y, Zhu ZM, Li TC, Wang LH, Chen

HY, Chen YD, Huang CL, Qu P, Yao C, Wang B, Chen

GH, Wang ZM, Xu ZY, Bai J, Lu D, Shen YH, Guo

F, Liu MY, Yang Y, Ding YC, Yang Y, Tian HT, Ding

QA, Li LN, Yang XC and Hu X. Intracoronary infusion

of Whartonꞌs jelly-derived mesenchymal stem cells in

acute myocardial infarction: double-blind, randomized

controlled trial.
BMC Med. (2015) 13: 162.
Gaffney J, Matou-Nasri S, Grau-Olivares M and

Slevin M. Therapeutic applications of hyaluronan.

Mol. BioSyst
. (2010) 6: 437-43.
Prestwich GD and Kuo JW. Chemically-modified HA

for therapy and regenerative medicine.
Curr. Pharm.
Biotechnol
. (2008) 9: 242-5.
Browning MB, Russell B, Rivera J, Hook M and

Cosgriff-Hernandez EM. Bioactive hydrogels with

enhanced initial and sustained cell interactions.

Biomacromolecules
(2013) 14: 2225-33.
Hutson CB, Nichol JW, Aubin H, Bae H, Yamanlar

S, Al-Haque S, Koshy ST and Khademhosseini A.

Synthesis and characterization of tunable poly(ethylene

glycol): gelatin methacrylate composite hydrogels.

Tissue Eng. Part A
. (2011) 17: 1713-23.
Shi K, Wang YL, Qu Y, Liao JF, Chu BY, Zhang

HP, Luo F and Qian ZY. Synthesis, characterization,

and application of reversible PDLLA-PEG-PDLLA

copolymer thermogels
in-vitro and in-vivo. Sci. Rep .
(2016) 6: 19077.

Lakshmanan R, Kumaraswamy P, Krishnan UM and

Sethuraman S. Engineering a growth factor embedded

nanofiber matrix niche to promote vascularization for

functional cardiac regeneration.
Biomaterials (2016)
97: 176-95.

Nassiri SM, Khaki Z, Soleimani M, Ahmadi SH,

Jahanzad I, Rabbani S, Sahebjam M, Ardalan FA and

Fathollahi MS. The similar effect of transplantation

of marrow-derived mesenchymal stem cells with or

without prior differentiation induction in experimental

myocardial infarction.
J. Biomed. Sci. (2007) 14: 745-
55.

Davani EY, Brumme Z, Singhera GK, Cote HC,

Harrigan PR and Dorscheid DR. Insulin-like growth

factor-1 protects ischemic murine myocardium from

ischemia/reperfusion associated injury.
Crit. Care
(2003) 7: R176-83.

Tejada T, Tan L, Torres RA, Calvert JW, Lambert JP,

Zaidi M, Husain M, Berce MD, Naib H, Pejler G,

Abrink M, Graham RM, Lefer DJ, Naqvi N and Husain

A. IGF-1 degradation by mouse mast cell protease 4

promotes cell death and adverse cardiac remodeling

days after a myocardial infarction.
Proc. Nat. Acad.
Sci. U S A
(2016) 113: 6949-54.
Scheinowitz M, Abramov D, Kotlyar A, Savion N

and Eldar M. Continuous administration of insulin-

like growth factor-I and basic fibroblast growth factor

does not affect left ventricular geometry after acute
myocardial infarction in rats. Int. J. Cardiol . (1998)
63: 217-21.

Hwang H and Kloner RA. The combined administration

of multiple soluble factors in the repair of chronically

infarcted rat myocardium.
J. Cardiovasc. Pharmacol .
(2011) 57: 282-6.

Zhang H, Wang H, Li N, Duan CE and Yang YJ.

Cardiac progenitor/stem cells on myocardial infarction

or ischemic heart disease: what we have known from

current research.
Heart Fail. Rev. (2014) 19: 247-58.
Shafiq M, Lee SH, Jung Y and Kim SH. Strategies for

recruitment of stem cells to treat myocardial infarction.

Curr. Pharm. Des
. (2015) 21: 1584-97.
van Zuylen VL, den Haan MC, Geutskens SB, Roelofs

H, Fibbe WE, Schalij MJ and Atsma DE. Post-

myocardial infarct inflammation and the potential role

of cell therapy.
Cardiovasc. Drugs Ther . (2015) 29:
59-73.

Kuraitis D, Ruel M and Suuronen EJ. Mesenchymal

stem cells for cardiovascular regeneration.
Cardiovasc.
Drugs Ther
. (2011) 25: 349-62.
Kalaszczynska I and Ferdyn K. Whartonꞌs jelly derived

mesenchymal stem cells: future of regenerative

medicine? Recent findings and clinical significance.

Biomed. Res. Int
. (2015) 2015: 430847.
Padin-Iruegas ME, Misao Y, Davis ME, Segers

VF, Esposito G, Tokunou T, Urbanek K, Hosoda T,

Rota M, Anversa P, Leri A, Lee RT and Kajstura J.

Cardiac progenitor cells and biotinylated insulin-like

growth factor-1 nanofibers improve endogenous and

exogenous myocardial regeneration after infarction.

Circulation
(2009) 120: 876-87.
Zhang GW, Gu TX, Guan XY, Sun XJ, Qi X, Li XY,

Wang XB, Lv F, Yu L, Jiang DQ and Tang R. HGF and

IGF-1 promote protective effects of allogeneic BMSC

transplantation in rabbit model of acute myocardial

infarction.
Cell Prolif. (2015) 48: 661-70.
Chen CH, Wang SS, Wei EI, Chu TY and Hsieh PC.

Hyaluronan enhances bone marrow cell therapy for

myocardial repair after infarction.
Mol. Ther. (2013)
21: 670-9.

Hasan A, Khattab A, Islam MA, Hweij KA, Zeitouny

J, Waters R, Sayegh M, Hossain MM and Paul A.

Injectable Hydrogels for Cardiac Tissue Repair after

Myocardial Infarction.
Adv. Sci. (Weinh) . (2015) 2:
1500122.

Maeda H, Nakamura H and Fang J. The EPR effect

for macromolecular drug delivery to solid tumors:

Improvement of tumor uptake, lowering of systemic

toxicity, and distinct tumor imaging
in-vivo. Adv. Drug
Deliv. Rev
. (2013) 65: 71-9.
Lin CC and Metters AT. Hydrogels in controlled

release formulations: network design and mathematical

modeling.
Adv. Drug Deliv. Rev. (2006) 58: 1379-408.
Kim SW, Bae YH and Okano T. Hydrogels: swelling,

drug loading, and release.
Pharm. Res. (1992) 9: 283-
90.

Jaikumar D, Sajesh KM, Soumya S, Nimal TR,

Chennazhi KP, Nair SV and Jayakumar R. Injectable

alginate-O-carboxymethyl chitosan/nano fibrin

composite hydrogels for adipose tissue engineering.

Int. J. Biol. Macromol
. (2015) 74: 318-26.
Nicodemus GD and Bryant SJ. Cell encapsulation

in biodegradable hydrogels for tissue engineering

applications.
Tissue Eng. Part B. Rev. (2008) 14: 149-
65.

Zhang H, Zhou L and Zhang W. Control of scaffold

degradation in tissue engineering: a review.
Tissue
Eng. Part B. Rev
. (2014) 20: 492-502.
Yildirimer L and Seifalian AM. Three-dimensional

biomaterial degradation - Material choice, design

and extrinsic factor considerations.
Biotechnol .Adv.
(2014) 32: 984-99.

Madihally SV and Matthew HW. Porous chitosan

scaffolds for tissue engineering.
Biomaterials (1999)
20: 1133-42.

Simitzis J, Soulis S, Triantou D, Zoumpoulakis

L and Zotali P. Synthesis and characterization of

hydrolytically degradable copolyester biomaterials

based on glycolic acid, sebacic acid and ethylene

glycol.
J. Mater. Sci. Mater. Med. (2011) 22: 2673-84.
Ruvinov E, Leor J and Cohen S. The promotion of

myocardial repair by the sequential delivery of IGF-

1 and HGF from an injectable alginate biomaterial in

a model of acute myocardial infarction.
Biomaterials
(2011) 32: 565-78.

Toh WS and Loh XJ. Advances in hydrogel delivery

systems for tissue regeneration.
Mater. Sci. Eng. C
Mater. Biol. Appl
. (2014) 45: 690-7.
Geckil H, Xu F, Zhang X, Moon S and Demirci U.

Engineering hydrogels as extracellular matrix mimics.

Nanomedicine (Lond)
(2010) 5: 469-84.
Alpert JS, Thygesen K, Antman E and Bassand

JP. Myocardial infarction redefined--a consensus

document of The Joint European Society of Cardiology/

American College of Cardiology Committee for the

redefinition of myocardial infarction.
J. Am. Coll.
Cardiol
. (2000) 36: 959-69.